Greenland Mines
Explores Greenland minerals alongside a biotech program for ALS.
Something off on this page? Send us feedback.
Profile
Mining exploration at the Skaergaard Project in southeast Greenland sits alongside a biotechnology division centered on KLTO-202 for ALS. The company holds a controlling interest in Skaergaard while pursuing an early-stage, two-division strategy.
Operating two early-stage divisions, mining focuses on exploration and development of the Skaergaard Project in southeast Greenland, while biotechnology centers on KLTO-202 for amyotrophic lateral sclerosis. The common stock trades on Nasdaq under GRML. The Greenland Mines acquisition gave the company a controlling interest in Skaergaard and an option on the remainder.
Planned acquisition of the Sarfartoq rare-earth project remains subject to closing conditions and Greenland government approval. Execution relies on two full-time employees and consultants as the company advances the mineral-exploration interest and biotech program. This structure combines an exploration-stage mineral business with a therapeutic program in one listed issuer.
Company facts
Key statistics
Year to date −55.7% · Average volume (30d) 410.7K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 17, 2026Q2 FY26 | — | −$1.50 | — | — | — | — | −2.06% |
| May 20, 2026Q1 FY26 | — | −$0.15 | — | — | — | — | −0.05% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$1.6M | −$1.9M | −$1.9M | −$1.8M | −$9.5M | −$5.5M | |
| Net income | −$2.2M | −$4.1M | −$2.9M | −$1.3M | −$13.9M | −$3.7M | |
| Diluted EPS | −$4.06 | −$6.00 | −$2.43 | −$0.91 | −$7.50 | −$1.45 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $9.3M · Total debt $298.0K · Total assets $65.0M · Shareholders' equity $57.9M
Dividends
No dividends on record.
Ownership
Shares outstanding 3.01M · Float 2.57M · 85.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Jeff LeBlanc · officer: Chief Financial Officer | 110.4K | 3.67% | Form 4 | Aug 25, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 25, 2026 | Jeff LeBlanc | officer: Chief Financial Officer | +14,000 | $9.72 |
| Jul 22, 2026 | Jason David Sawyer | director | +240,000 | $0.2331 |
| Jul 20, 2026 | Jon McGarity | director | +140,000 | $0.1773 |
| Jul 16, 2026 | Jeff LeBlanc | officer: Chief Financial Officer | +1,400,000 | $0.1752 |
| Jun 25, 2026 | Riad Hussein El-Dada | director | −175,000 | $0.2317 |
Peers
- Platinum Group Metals
Develops a large South African palladium and platinum project
- Sibanye Stillwater (ADR)
Major producer of platinum-group metals across South Africa and the US
- Critical Metals
Advances the Tanbreez heavy-rare-earth project in Greenland
- MP Materials
Integrated U.S. producer of NdPr and rare-earth magnets
- Ionis Pharmaceuticals
Genetic-medicine programs for ALS, including QALSODY
- Clene
Late-stage CNM-Au8 program for amyotrophic lateral sclerosis
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Greenland Mines | $4.92 | +0.61% | $14.7M | — | — | — | — |
| Platinum Group Metals | $1.51 | +1.23% | $191.8M | — | — | — | — |
| Sibanye Stillwater (ADR) | $12.06 | −0.33% | $8.56B | — | — | 1.1 | +55.9% |
| Critical Metals | $7.27 | +1.92% | $1.05B | — | — | 1,360.8 | −44.2% |
| MP Materials | $56.28 | +0.23% | $9.99B | — | 173.8 | 32.7 | +89.0% |
| Ionis Pharmaceuticals | $61.05 | +0.02% | $10.15B | — | — | 11.6 | −40.7% |
| Clene | $4.23 | −1.17% | $54.1M | — | — | 274.4 | +233.3% |
| Median | — | 173.8 | 32.7 | +55.9% |